Stocklytics Platform
EFTR
eFFECTOR Therapeutics
EFTRW4
$0.00arrow_drop_up399.99%$0.00
Penny Stock
EFTR
EFTRW4

$0.00

arrow_drop_up399.99%

Performance History

Chart placeholder
Key Stats
Open$0.00
Prev. Close$0.00
EPS-0.90
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap-
PE Ratio-
LOWHIGH
Day Range0.00
0.00
52 Week Range0.00
0.18
Ratios
Revenue-
EBITDA Margin %-
EPS-0.90

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

About eFFECTOR Therapeutics (EFTRW)

eFFECTOR Therapeutics, Inc. (EFTRW) is a biopharmaceutical company that focuses on the discovery and development of selective translation regulators (STRs) for the treatment of cancer and other serious diseases. The company utilizes its innovative discovery platform and deep understanding of cancer biology to identify novel STRs that can modulate key disease pathways. With a mission to transform the lives of patients, eFFECTOR Therapeutics is dedicated to advancing its pipeline of potential therapeutics.
As of the most recent stock price history available, eFFECTOR Therapeutics, Inc. (EFTRW) has experienced fluctuations in its stock price. Investors should review the latest quote to get the most up-to-date information on the stock. By staying informed about the latest news and developments, investors can make more informed decisions about their investment strategies.
Sector
Industry
CEO
Headquarters
Employees
0
Exchange
NASDAQ
add eFFECTOR Therapeutics to watchlist

Keep an eye on eFFECTOR Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is eFFECTOR Therapeutics's (EFTRW) price per share?

The current price per share for eFFECTOR Therapeutics (EFTRW) is $0. The stock has seen a price change of $0 recently, indicating a 0% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for eFFECTOR Therapeutics (EFTRW)?

For eFFECTOR Therapeutics (EFTRW), the 52-week high is $0.19, which is 6.17K% from the current price. The 52-week low is $0, the current price is 900% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is eFFECTOR Therapeutics (EFTRW) a growth stock?

eFFECTOR Therapeutics (EFTRW) has shown an average price growth of 0.41% over the past three years. It has received a score of 0 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying eFFECTOR Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is eFFECTOR Therapeutics (EFTRW) stock price performance year to date (YTD)?

As of the latest data, eFFECTOR Therapeutics (EFTRW) has a year-to-date price change of -97.54%. Over the last three months, the change has been -89.09%. Over the past six months, the figure is -98%.
help

Is eFFECTOR Therapeutics (EFTRW) a profitable company?

eFFECTOR Therapeutics (EFTRW) has a net income of -$35.81M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$33.84M. Furthermore, the EBITDA is -$32.59M.
help

What is the market capitalization of eFFECTOR Therapeutics (EFTRW)?

eFFECTOR Therapeutics (EFTRW) has a market capitalization of . The average daily trading volume is 28K, indicating the stock's liquidity and investor engagement.

News

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level

Stocklytics Platform

© 2024 Stocklytics.com All rights reserved.

Stocklytics.com is not a financial advisor, and all data and information provided on this website are for informational purposes only. The content on Stocklytics.com is not intended to be a substitute for professional financial advice. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions. Stocklytics.com makes no representations or warranties regarding the accuracy, completeness, or suitability of any information provided and is not liable for any errors or omissions, or for any losses incurred as a result of reliance on the information provided on this website.

Stocklytics Discord public channelStocklytics X Social Media